Remove Medicine Remove Pharma Companies Remove Production
article thumbnail

Valuation of Pharma Companies: 5 Key Considerations

Drug Patent Watch

"5 Key Considerations for Valuing Pharma Companies As the pharmaceutical industry continues to evolve, accurately valuing pharma companies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.

article thumbnail

Hataali wins US patent for the use of blockchain in advanced medicinal therapy products

Pharma Mirror

London, ATMPS Ltd/Hataali – the leader in blockchain-based data sharing platforms for advanced therapies – announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines.

Medicine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inflation threatens supply of life-saving generics to Europe

Pharmaceutical Technology

On November 16, 2022, Medicines for Europe (MFE), the generics and biosimilars body, called for EU and national reforms to improve the security of medicine supplies, including tackling the impact of inflation on the security of essential medicine supplies with smart procurement guidelines for medicine.

Medicine 246
article thumbnail

MHRA publishes guidance on medicine regulation after Brexit

pharmaphorum

The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of the year. The concern is that UK patients will face delays to receiving the latest medicines because of the changes to the regulatory system.

article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

article thumbnail

Top 10 Most Environmentally Sustainable Pharma Companies in 2023/2024

XTalks

There was also significant variability in emissions, up to five times, between pharma companies with comparable revenues. For example, Proctor & Gamble was found to emit almost five times more CO 2 e than Johnson & Johnson despite the two companies having similar revenue levels and producing similar lines of products.

article thumbnail

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.

Medicine 290